SPECTRUM TURBO-JECT PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER

K081690 · Cook, Inc. · FOZ · Jul 14, 2008 · General Hospital

Device Facts

• Record ID: K081690
• Device Name: SPECTRUM TURBO-JECT PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER
• Applicant: Cook, Inc.
• Product Code: FOZ · General Hospital
• Decision Date: Jul 14, 2008
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 880.5200
• Device Class: Class 2

Intended Use

The Spectrum Turbo-JeCT PICC is indicated for short- or long-term use for venous pressure monitoring, blood sampling, administration of drugs and fluids, and for use with power injectors for delivery of contrast in CT studies. The catheter is impregnated with the antimicrobials minocycline and rifampin to help provide protection against catheterrelated bloodstream infections (CRBSIs). The Spectrum Turbo-JeCT PICC is indicated for multiple injections of contrast media through a power injector. The maximum pressure limit setting for power injectors used with the Spectrum Turbo-JeCT PICC may not exceed 325 psi and the flow rate may not exceed the maximum flow rate indicated.

Device Story

Radiopaque polyurethane peripherally inserted central venous catheter (PICC); 60 cm length; 4/5 Fr single or 5 Fr double lumen configurations. Impregnated with minocycline and rifampin for antimicrobial protection against CRBSIs. Used for venous access, monitoring, and power injection of contrast media (max 325 psi). Operated by clinicians in clinical settings. Facilitates CT imaging via power injector compatibility. Benefits include reduced infection risk and reliable high-pressure contrast delivery.

Clinical Evidence

Bench testing only. No clinical data provided. Testing included flow rate, static burst failure, cyclic fatigue, liquid/air leakage, tensile/bond strength, stiffness, shelf life, sterility, and biocompatibility.

Technological Characteristics

Radiopaque polyurethane catheter; antimicrobial impregnation (minocycline/rifampin); 4-5 Fr diameters; 60 cm length. Power injector compatible (up to 325 psi).

Indications for Use

Indicated for patients requiring short- or long-term venous access for pressure monitoring, blood sampling, fluid/drug administration, and power-injected contrast delivery in CT studies.

Regulatory Classification

Identification

An intravascular catheter is a device that consists of a slender tube and any necessary connecting fittings and that is inserted into the patient's vascular system for short term use (less than 30 days) to sample blood, monitor blood pressure, or administer fluids intravenously. The device may be constructed of metal, rubber, plastic, or a combination of these materials.

Predicate Devices

• Cook Spectrum Silicone Catheter (K021557)
• Cook Turbo-JeCT PICC (K072625)

Submission Summary (Full Text)

{0}------------------------------------------------

K081690-Response to Request for Additional Information Spectrum® Turbo-JeCTTM PICC Cook Incorporated

## 510(k) Summary

## Submitted By:

\$\Upsilon0\gamma/6\,90\$

JUL 1 4 2008

Nathan Simon, M.S. Regulatory Affairs Specialist Cook Incorporated 750 Daniels Way, PO Box 489 Bloomington, IN 47402 812-339-2235

### Device:

| Trade Name: | Spectrum® Turbo-JeCT™ Peripherally Inserted<br>Central Venous Catheter (PICC) |
|--------------------------|------------------------------------------------------------------------------------------|
| Proposed Classification: | Percutaneous, Implanted, Short- and Long-Term<br>Intravascular Catheter<br>(FOZ and LJS) |

### Indications for Use:

The Spectrum Turbo-JeCT PICC is indicated for short- or long-term use for venous pressure monitoring, blood sampling, administration of drugs and fluids, and for use with power injectors for delivery of contrast in CT studies. The catheter is impregnated with the antimicrobials minocycline and rifampin to help provide protection against catheterrelated bloodstream infections (CRBSIs). The Spectrum Turbo-JeCT PICC is indicated for multiple injections of contrast media through a power injector. The maximum pressure limit setting for power injectors used with the Spectrum Turbo-JeCT PICC may not exceed 325 psi and the flow rate may not exceed the maximum flow rate indicated.

| Catheter Size | Maximum Flow Rate* | Injection Pressure<br>Limit Setting |
|-------------------|--------------------|-------------------------------------|
| 4 Fr Single Lumen | 4 ml/sec | 325 psi |
| 5 Fr Single Lumen | 7 ml/sec | 325 psi |
| 5 Fr Double Lumen | 5 ml/sec | 325 psi |

*Flow rates achieved using room temperature Omnipaque 300® contrast and verified using a Medrad Stellant® CT injector system. Omnipaque 300 has a viscosity of 11.8 centipoise at room temperature (20 degrees (). A change in temperature on viscosity of the contrast medium used will result in a change in achievable flow rates. Omnipague 300® is a registered trademark of Amersham Health, New Jersey.

### Predicate Devices:

The Spectrum Turbo-JeCT PICC Catheter is similar in terms of intended use, materials of construction and technological characteristics to predicate devices Cook Spectrum Silicone Catheter and Cook Turbo-JeCT PICC catheters that were found substantially equivalent under Premarket Notification #K021557, May 30, 2003 and #K072625, December 13, 2007, respectively.

{1}------------------------------------------------

# Device Description:

The Spectrum Turbo-JeCT catheter is a radiopaque polyurethane peripherally inserted central venous catheter impregnated with antimicrobials and intended for short- or longterm use. The Spectrum Turbo-JeCT PICCs are 60 cm in length and available in 4 and 5 Fr single lumen and 5 Fr double lumen configurations.

The set components include an introducer needle, wire guide, locking Peel-Away introducer, 12cc syringe, drape, injection cap, catheter fixation device, tape measure, safety scalpel, and a hydrophilic-coated wire guide obturator for non-over-the-wire versions.

# Substantial Equivalence:

Cook currently markets the PICC Catheter which is considered substantially equivalent to the Spectrum Turbo-JeCT PICC Catheter. The identical indications for use, principles of operation, similar materials of construction, and technological characteristics of the Spectrum Turbo-JcCT PICC Catheter as compared to the predicate devices support a determination of substantial equivalency.

# Test Data:

·

The Spectrum Turbo-JeCT PICC Catheter was subjected to the following tests to assure reliable design and performance under the specified testing parameters. These tests were comprised of:

- 1. Flow rate tests
- 2. Static burst failure pressure tests
- 3. Cyclic fatigue test
- 4. Liquid leakage under pressure test
- Air leakage during aspiration test റ
- 6. Tensile strength tests
- 7. Bond strength tests
- 8. Stiffness test
- 9. Shelf life tests
- 10. Sterility tests
- Biocompatibility tests 11.

The results of these tests provide reasonable assurance that the device has been designed and tested to assure conformance to the requirements for its use as a PICC catheter.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized eagle-like symbol on the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Nathan Simon Regulatory Affairs Specialist Cook, Incorporated P.O. Box 489 Bloomington, Indiana 47402 IJUL 1 4 2008

Re: K081690

Trade/Device Name: Spectrum® Turbo-JeCT™ Peripherally Inserted Central Venous Catheter (PICC) Regulation Number: 21 CFR 880.5200 Regulation Name: Intravascular Catheter Regulatory Class: II Product Code: FOZ, LJS Dated: June 16, 2008 Received: June 17, 2008

Dear Mr. Simon:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

### Page 2 - Mr. Simon

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-[See Below For Phone Numbers]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Anthony D. norton
Shiela J. Perez

Chiu Lin. Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

510(k) Number (if known):

Device Name: Spectrum® Turbo-JeCT™ Peripherally Inserted Central Venous Catheter (PICC)

Indications for Use:

The Spectrum Turbo-JeCT PICC is indicated for short- or long-term use for venous pressure monitoring, blood sampling, administration of drugs and fluids, and for use with power injectors for delivery of contrast in CT studies. The catheter is impregnated with the antimicrobials minocycline and rifampin to help provide protection against catheterrelated bloodstream infections (CRBSIs). The Spectrum Turbo-JeCT PICC is indicated for multiple injections of contrast media through a power injector. The maximum pressure limit setting for power injectors used with the Spectrum Turbo-JeCT PICC may not exceed 325 psi and the flow rate may not exceed the maximum flow rate indicated.

| Catheter Size | Maximum Flow Rate* | Injection Pressure<br>Limit Setting |
|-------------------|--------------------|-------------------------------------|
| 4 Fr Single Lumen | 4 ml/sec | 325 psi |
| 5 Fr Single Lumen | 7 ml/sec | 325 psi |
| 5 Fr Double Lumen | 5 ml/sec | 325 psi |

*Flow rates achieved using room temperature Omnipaque 3000 contrast and verified using a Medrad Stellant® CT iniector system. Omnipaque 300 has a viscosity of 11.8 centipoise at room temperature (20 degrees C). A change in temperature on viscosity of the contrast medium used will result in a change in achievable flow rates. Omnipaque 300® is a registered trademark of Amersham Health, New Jersey.

Cintin Vm

(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices

510(k) Number: K481640

Prescription Use X (Per 21 CFR 801 Subpart D) OR

Over-the-Counter Use (21 CFR 807 Subpart C)

## (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Company Confidential

4